AnaptysBio Stock Forecast
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 46.21 0.00%
ANAB analyst consensus
Consensus (8 analysts)
strong_buy
Avg. price target
$87.25+88.81%
- Strong buy 3
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering AnaptysBio (2026-10-08), 8 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $87.25, with a high estimate of $140.00 and a low estimate of $60.00. The average target implies upside of 88.8% from the current price of $46.21.
The spread between the highest and lowest targets is 133.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ANAB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 38% |
| Buy | 5 | 63% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $60.00 | +29.84% |
| Average target | $87.25 | +88.81% |
| High target | $140.00 | +202.96% |